Please login to the form below

Not currently logged in
Email:
Password:

oseltamivir

This page shows the latest oseltamivir news and features for those working in and with pharma, biotech and healthcare.

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

Roche’s Xofluza pill wins FDA approval for post-exposure flu prevention

It has already been shown to be effective against a wide range of flu viruses, including those resistant to Roche’s now off-patent and former blockbuster flu treatment, Tamiflu (oseltamivir).

Latest news

  • Roche scores another FDA approval for Xofluza Roche scores another FDA approval for Xofluza

    oseltamivr. The approval was based on results from Roche’s phase 3 CAPSTONE-2 trial of Xofluza, compared to oseltamivir or placebo, in people aged 12 or over, who met the ... However, similar efficacy results were seen between Xofluza and oseltamivir

  • UK bans some drug exports to preserve NHS stocks UK bans some drug exports to preserve NHS stocks

    It applies mainly to hormone replacement therapies but also includes all adrenaline pens, hepatitis B vaccines and the influenza drug oseltamivir, sold by Roche as Tamiflu, amongst other drugs.

  • Roche’s flu drug Xofluza scores phase 3 primary endpoint Roche’s flu drug Xofluza scores phase 3 primary endpoint

    It has already been shown to be effective against a wide range of flu viruses, including those resistant to Roche’s now off-patent and former blockbuster flu treatment, Tamiflu (oseltamivir). ... Roche is keen to produce more evidence of the

  • Roche’s new flu pill Xofluza approved in US Roche’s new flu pill Xofluza approved in US

    Xofluza significantly reduced the duration of flu symptoms compared to placebo, and demonstrated similar efficacy compared to oseltamivir. ... Analysts say the new treatment will have to generate more evidence of significant benefits in these high risk

  • Encouraging data for Roche flu drug ahead of FDA decision Encouraging data for Roche flu drug ahead of FDA decision

    Analysts say the new treatment will have to generate more evidence of significant benefits in these high risk groups in order for healthcare systems to switch away from generic oseltamivir.

More from news
Approximately 0 fully matching, plus 35 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....